INTRODUCTION
For most of the twentieth century little important progress was made in the management of patients with Ph-positive (or BCR-ABL-positive) chronic myeloid leukemia (CML). The minority of patients who were treated by allogeneic stem cell transplantation could expect to be cured if they survived the procedure but for the majority interferon-alfa alone or in combination with cytarabine offered the prospect of prolonging survival by one to two years compared with earlier use of conventional cytotoxic drugs. 1, 2 The introduction into clinical practice of imatinib mesylate in 1998 proved to be a remarkable contribution to the management of patients with CML in chronic phase (CP) and this drug at 400 mg daily has now become the recommended initial treatment for all adult patients throughout the world. The majority of patients can now expect to survive ten, twenty or more years. 3, 4 It is even possible that some patients treated for a number of years can stop the imatinib and be regarded as cured of their leukemia. 5 With this background it is important to recognise that although the majority of patients fare extremely well when treated with imatinib as a single agent, a significant minority do not. 4 Given the current availability of both allogeneic stem cell transplantation and second generation tyrosine kinase inhibitors it is essential to identify at the earliest opportunity these patients so that alternative treatment strategies can be introduced.
In 2006 Baccarani and colleagues on behalf of the European LeukemiaNet published a series of empirical recommendations designed to help clinicians identify CML-CP patients responding poorly to imatinib at standard dosage 2 ( Table 1 ). The recommendations were based on assessing response to treatment at various timepoints using specific hematologic, cytogenetic and molecular criteria. Based on these criteria, patients could be classified as 'failure' or 'suboptimal response'. Additional features defined at diagnosis or during the course of the disease indicated the need for closer follow-up of individual patients and were classified as 'warnings'. Though not based on detailed evaluation of large numbers of patients followed for many years, these recommendations did indeed prove very valuable in helping clinicians plan therapy for individual patients and have gained wide acceptance on both sides of the Atlantic and elsewhere. Here we show that the clinical outcome for 224 newly diagnosed CML-CP patients treated in a single institution do indeed conform very well with results that could be anticipated from application of the recommendations only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From but we note certain discordances that may prove useful when the recommendations are revised. . Patients received imatinib 400 mg daily by mouth as previously described. 4 Bone marrow morphology and cytogenetics were assessed at diagnosis and then every 3 months until patients achieved CCyR. Thereafter patients were monitored by realtime quantitative PCR (RQ-PCR, see below) and annual bone marrow examinations.
PATIENTS AND METHODS

Patient characteristics and treatment
Between
CCyR was defined by the failure to detect any Philadelphia (Ph) chromosomepositive metaphases in two consecutive bone marrow examinations with a minimum of 30 metaphases examined and major cytogenetic response (MCyR) was defined by combining the number of complete and partial cytogenetic responses (≤35% Phpositive metaphases). Cytogenetic relapse (loss of CCyR) was defined by the detection of one or more Ph-positive marrow metaphases, also confirmed by a subsequent study, in a patient who had previously achieved CCyR. Bone marrow examination was triggered by a rise in BCR-ABL transcript numbers to a level consistent with cytogenetic relapse. 6 Disease progression was defined when the leukemia satisfied criteria for advanced phase (accelerated or blastic phases). MCyR, CCyR and major molecular response (MMR) respectively. Kinase domain (KD) mutations were detected in 17 patients; 11 were in CHR (of whom 7 were still in CCyR) and 6 had lost their CHR or progressed to advanced phase. 29 patients discontinued the imatinib therapy while still in CP, 8 due to toxicity and 21 to unsatisfactory response. Additional cytogenetic abnormalities in Ph positive cells (ACAs) emerged during therapy in 22 patients, of whom 2 were in raised count CP, 14 were in CHR, and in the remaining 6 the ACAs were detected only after progression to advanced phase. Other new cytogenetic abnormalities in Ph negative cells were detected in 8 patients. Thirty-four patients lost their CHR, 25 progressed to accelerated or blastic phase and 13 died. The dose of imatinib was increased above 400 mg day in 94 (42%) patients; 21 patients (9.4%) had the imatinib increased during the first year of therapy.
Molecular studies
BCR-ABL transcripts were measured in the blood at 6 to 12 week intervals using RQ-PCR as described previously.
6,8-10 Results were expressed as percent ratios relative to an ABL internal control and as log 10 reductions compared with the standardised median value for the 30 untreated patients that we used in the IRIS study. 8,11 MMR was defined as a 3 log reduction in transcript levels 11 based on two consecutive molecular studies and complete molecular response (CMR) was defined as two consecutive samples with no detectable transcripts provided that control gene copy numbers were adequate. Samples obtained for RQ-PCR were also analyzed at regular intervals for KD mutations as described elsewhere 4 .
Statistical Methods
Probabilities of overall survival (OS) and progression-free survival (PFS) were calculated using the Kaplan-Meier method. PFS was defined as survival without evidence of accelerated or blastic phase disease. 7 The probabilities of cytogenetic response and cytogenetic relapse were calculated using the cumulative incidence procedure, where cytogenetic response or relapse were the events of interest and imatinib discontinuation, death and disease progression were the competitors. For OS and PFS analysis, patients were censored at the time of stem cell transplant.
Univariate analyses to identify prognostic factors for OS, PFS, cytogenetic response only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From and cytogenetic relapse were carried out using the log-rank test. Variables found to be significant at the p<0.25 level were entered into a proportional hazards regression analysis using a forward stepping procedure, with standard boundaries of entry (0.05) and removal (0.10) of variables, to find the best model (SPSS 11.0.1 © ). The proportional hazards assumption was confirmed by adding a time-dependent covariate for each covariate. The influence of the emergence of KD mutations, emergence of ACAs, loss of a previously achieved CHR, loss of a previously achieved CCyR and loss of a previously achieved MMR on the different outcomes at any time during the follow-up was studied in a time-dependent Cox model. P-values were 2-sided and 95% confidence intervals (CI) computed.
RESULTS
The LeukemiaNet criteria for classifying patients as 'failure' were durable Eight, 37 and 45 patients were classified as failure at 3, 6 and 12 months respectively.
( Figure 1) . None of the patients classified as failure at 3 or 12 months later reversed their 'failure' status (i.e. at 12 or 18 months), whereas four of the 37 patients classified as failure at 6 months subsequently satisfied criteria for response. However of these four patients one was re-classified as failure at 18 months and a further two lost the previously achieved CCyR. Thus the classification criteria were robust as almost all patients classified as failure at a given time point continued to meet the failure criteria at subsequent time points (p always <0.0001).
Prognostic significance of LeukemiaNet criteria for failure at 3, 6, 12 and 18 months At each of the time points patients classified as failure had a significantly lower OS, PFS and probability of achieving CCyR than the patients classified as responders (Table 2 and Figure 2 ). For example, the patients classified as failure by the 12-month criteria had a significantly lower 5 year OS than responders (87.1% vs 95.1%, p=0.02), lower PFS (76% vs 90%, p=0.002) and lower probability of CCyR (26.7% vs 94.1%, p<0.0001). Patients classified as failure at any time point who did eventually achieve CCyR (after 18 months) had a significantly higher probability of losing their CCyR. For example, at 12 months the cumulative incidence of loss of CCyR for these patients was significantly higher than that of responders (51% vs 10.3%, p<0.0001). We found a de facto overlap between the definitions of suboptimal response and failure at 3 months because though 8 patients were classified as failure none of the remaining 216 patients were classified as suboptimal response. Table 2 shows the probabilities of OS, PFS, CCyR and loss of CCyR for the patients according to whether or not they met the definition for suboptimal response once the failure patients had been excluded. Suboptimal responders defined at 6 and 12 months had a significantly poorer PFS and lower probability of CCyR. Suboptimal responders by the 12 month criteria also had significantly worse survival. The 18 month criteria failed to identify patients with worse OS or PFS.
We combined the definitions of failure with suboptimal response at 6, 12 and 18 months, comparing at each time point outcomes for patients who met the criteria for failure or suboptimal response with that of "responders" (non-failure and non suboptimal). At 6 months "non-responders" had a significantly worst 5 year OS (86.6% vs 97.9%, p=0.04), PFS (70.0% vs 92%, p=0.001) and probability of CCyR (38.5% vs 96%, p<0.0001) than the "responding" patients. Similar results were obtained at 12 months, OS 86.7% vs 98.5 (p=0.01), PFS 75.3% vs 96.7 (p=0.0009) and CI of CCyR 52.2% vs 100% (p<0.0001). However patients classified as "nonresponders" at 18 months had OS and PFS similar to those of patients classified as "responders", namely 94.5% vs 97.4% (p=0.9) and 88.0% vs 95.4% (p=0.4).
We then considered as "non responder" patients who had met either the criteria for only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From failure or suboptimal response at 3, 6 or 12 months and compared their OS, PFS and probability of CCyR with those of patients who never met any of the criteria for failure or suboptimal responded at either 3, 6 or 12 months. Non responders had a significantly worse OS (85% vs 98.4%, p=0.003), PFS (70.4% vs 95.9, p<0.0001) and probability of CCyR (51.4% vs 100%, p<0.0001) (Figure 3 ).
Warnings
We did not routinely study patients for the presence of a 9q+ deletion, so we could not explore its prognostic meaning. Patients in the Sokal high group risk and patients with ACAs at diagnosis fared worse (table 3) . However, the failure to achieve MMR at 12 months or the presence of chromosomal abnormalities in Ph-negative cells did not have any impact in OS or PFS (table 3) .
Prognostic significance of MMR
Whether we considered the whole population or limited our analysis to patients in CCyR, the achievement of MMR at 12 or 18 months failed to confer any benefit in 5-year PFS or OS. We further explored the prognostic implication of achieving MMR by studying the effect of molecular response on the probability of losing a CCyR.
Patients in CCyR who had failed to achieve MMR at 12 or 18 were more likely to lose their CCyR than patients who did achieve MMR, 23.6% vs 2.6% (p=0.04) and 24.6% vs 0% (p=0.006) respectively (Figure 3) Table 3 summarizes OS, PFS and probability of achieving CCyR for the 224 patients in this analysis according to each of the components that define failure, suboptimal response or warnings at the various time-points in the LeukemiaNet recommendations.
Contribution of the individual criteria to the identification of the high risk patients
In order to study the relative contribution of these individual components to the identification of high risk patients we performed 3 landmark analysis for PFS using the variables defined at 6, 12 and 18 months (table 3) .
At six months, the only independent predictors for PFS were (1) being in CHR (RR=5.9, p=0.012), (2) being in MCyR (RR=3.3, p=0.017), and (3) ACAs at diagnosis (RR=0.2, p=0.034). At 12 months, the only independent predictors for PFS only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From were (1) being in CCyR (RR=4.5, p=0.02), and (2) prior loss of CCyR (RR=0.24, p=0.036). At 18 months the only independent predictor for PFS was being in CCyR (RR=6.9, p=0.005).
Both at 6 and 12 months the multivariate analysis showed that the cytogenetic criteria used to define suboptimal response were more predictive than the ones used to define failure. When we sub-classified the patients according to their cytogenetic response at 6 months as (a) >95% Ph+, n=34, (b) 36 to 95% Ph+, n=28 and (c) MCyR, n=157 we found that the probabilities for 5-year PFS were 72.8%, 74.9% and 91.5% (p=0.003) We found that the patients classified as 'failure' had a lower survival, a lower PFS and a lower probability of achieving CCyR, and a higher probability of losing their CCyR if they did achieve it (Table 2 and Figure 2 ). Furthermore almost all the individual parameters that comprise the definition of failure at the various time-points were per se significant predictors for those outcomes. We could not examine the impact on survival and PFS of finding a TK mutation highly resistant to imatinib as we found such mutations in only two cases. We found a complete 'overlap' between the definitions of 'failure' and 'suboptimal response' at 3 months as all the patients classified as 'non-failure' were in fact in CHR at 3 months. When patients classified as failure were excluded from analysis, we found that the criteria used to define suboptimal response at 6 months significantly discriminated between patients with good and poor PFS and probability of achieving CCyR. The 12-month criteria significantly discriminated patients with good and poor OS, PFS and probability of achieving CCyR; for example, with the 12-month criteria PFS for sub-optimal responders was 73.4% vs. 96.1% for responders (Table 2) . Furthermore, responders without 'warnings' had a 5 year PFS of 100% (data not shown).
The prognostic significance of achieving MMR at 12 or 18 months has been controversial for some while. In our analysis the definitions of 'warning' at 12 months and of 'suboptimal response' at 18 months, both of which are based predominantly on molecular responses, did not have prognostic impact on PFS or survival. The initial report in the IRIS study found a marginal advantage in PFS for those patients in CCyR who had also achieved MMR by 12 months 11 but this was not confirmed by a subsequent analysis with 5 years follow-up For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From effective therapy. We compared the probability of losing CCyR between these two groups and indeed patients who had achieved MMR either at 12 and 18 months had a significantly lower probability of losing their CCyR (Fig 4) . The same explanation, namely a change of therapy, could explain the fact that loss of MMR was associated with loss of CCyR (RR= 5.0, p=0.02, data not shown) but did not adverse influence OS or PFS.
We found that the cytogenetic criteria used to define suboptimal response at 6 and 12 months identified better the patients with bad prognosis than the cytogenetic criteria used to define failure. For instance, at 12 months patients who were in MCyR but not in CCyR had a PFS very similar to that of patients who had failed entirely to achieve MCyR (81.5% vs 76.3%, p=0.4), while they had a PFS significantly different from that of the CCyR patients (81.5% vs 96.2%, p=0.01). This suggests that the recommendations might be improved by using the current cytogenetic criteria for suboptimal response at 6 and 12 months to define 'failure'. And indeed when we pool the patients classified as failure and those classified as suboptimal response either at 6 or 12 months we found a more accurate prediction of the poor risk patients than when we consider only patients who met the failure criteria, with the additional benefit that poor risk patients can be identified at 12 months rather than at 18 months (Figure 3 ).
Additional cytogenetic abnormalities in Ph positive clones both at diagnosis and during follow-up are associated with poor outcomes. [13] [14] [15] In our study additional cytogenetic abnormalities at diagnosis were one of the independent adverse predictors for PFS in the 6 month analysis. They were present in 4 of the 6 patients who progressed within one year. The emergence of additional cytogenetic abnormalities on therapy at any time during the follow-up was an independent adverse prognostic factor for PFS (RR=10.5, p<0.0001). Our data therefore confirm the poor prognosis associated with the acquisition of additional cytogenetic abnormalities and provide some support for the recommendation that such patients should be re-classified as in accelerated phase.
14
We have reported previously that the acquisition of KD mutations is a poor prognostic factor for PFS in CP patients, some of whom had previously been treated with interferon-alfa
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, and also predicts for loss of CCyR in previously untreated patients 4 .
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In this series we identified 17 patients with 'acquired' KD mutations and showed that they too had a significantly inferior PFS in univariate analysis and higher loss of hematologic response in multivariate analysis. It should be noted however that the analysis performed for this study was not designed to assess the prognostic significance of KD mutations, since other extraneous variables entered into this analysis such as loss of CCyR and loss of CHR, for which KD mutations were strong independent predictors (data not shown), might have obscured the significance of KD mutations. value. Now that second line agents are readily available it may be time to refine the recommendations by combining some of the criteria that define 'failure' with some of the criteria that are currently used to define 'sub-optimal response'; this might identify at an rather earlier stage those patients who require alternative therapy.
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